

Angina (Angina Pectoris) - Pipeline Review, H1 2020

<https://marketpublishers.com/r/A2182360FBBEN.html>

Date: April 2020

Pages: 78

Price: US\$ 2,000.00 (Single User License)

ID: A2182360FBBEN

Abstracts

Angina (Angina Pectoris) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Angina (Angina Pectoris) - Pipeline Review, H1 2020, provides an overview of the Angina (Angina Pectoris) (Cardiovascular) pipeline landscape.

Angina pectoris is a term that describes chest pain caused by myocardial ischemia. It usually occurs on exertion and is relieved by rest. Angina generally is a symptom of coronary artery disease. In most severe cases, it occurs with minimal effort or at rest. Symptoms include anxiety, increased or irregular heart rate, paleness and cold sweat, and a feeling of doom. Risk factors include smoking, sedentary lifestyle, high blood fats or cholesterol, hypercholesterolemia.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Angina (Angina Pectoris) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Angina (Angina Pectoris) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Angina (Angina Pectoris) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Angina (Angina Pectoris) and features dormant and discontinued projects. The guide covers therapeutics under Development

by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Discovery stages are 2, 2, 3, 4 and 3 respectively.

Angina (Angina Pectoris) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Angina (Angina Pectoris) (Cardiovascular).

The pipeline guide reviews pipeline therapeutics for Angina (Angina Pectoris) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Angina (Angina Pectoris) (Cardiovascular) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Angina (Angina Pectoris) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Angina (Angina Pectoris) (Cardiovascular)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Angina (Angina Pectoris) (Cardiovascular).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Angina (Angina Pectoris) (Cardiovascular) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Angina (Angina Pectoris) - Overview

Angina (Angina Pectoris) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Angina (Angina Pectoris) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Angina (Angina Pectoris) - Companies Involved in Therapeutics Development

Angionetics Inc

Ark Therapeutics Ltd

Caladrius Biosciences Inc

G. Pohl-Boskamp GmbH & Co KG

Hemostemix Inc

Imbria Pharmaceuticals Inc

Jiangsu Hengrui Medicine Co Ltd

Kuhnle Pharmaceutical Co Ltd

Milestone Pharmaceuticals Inc

Signal Pharma Ltd

TSH Biopharm Corporation Ltd

VasThera Research Institute

XyloCor Therapeutics Inc

Angina (Angina Pectoris) - Drug Profiles

ACP-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alferminogene tadenovec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLBS-14 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLBS-16 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EG-011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etripamil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMB-1018972 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ivabradine hydrochloride SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KI-1007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nitroglycerin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranolazine ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Angina - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate PRDX2 for Cardiovascular Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XC-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Angina (Angina Pectoris) - Dormant Projects

Angina (Angina Pectoris) - Discontinued Products

Angina (Angina Pectoris) - Product Development Milestones

Featured News & Press Releases

Nov 16, 2019: Caladrius Biosciences reports positive results for CLBS16 from the ESCaPE-CMD trial at American Heart Association Scientific Sessions 2019

Oct 31, 2019: Caladrius Biosciences to participate at upcoming November conferences

Jun 04, 2019: Caladrius Biosciences completes enrollment in Phase 2 ESCaPE-CMD trial for Coronary Microvascular Dysfunction

Jul 18, 2018: Hemostemix announces first U.S. Patients treated in phase II clinical trial

Jun 19, 2018: Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina

Feb 07, 2017: FDA Grants Fast Track Designation To Angionetics' Generx Product Candidate, A One-Time Gene Therapy For Coronary Heart Disease

Sep 26, 2016: Espero Pharmaceuticals Announces the Availability of FDA-Approved GONITRO (Nitroglycerin) Sublingual Powder in the U.S.

Sep 12, 2016: Angionetics' Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease

Aug 31, 2016: Espero Pharmaceuticals Selects DDB Health and Alamo Pharma Services as Partners for the Launch of GONITRO (Nitroglycerin) Sublingual Powder

Jun 14, 2016: Espero Pharmaceuticals Receives FDA Approval for GONITRO (Nitroglycerin) Sublingual Powder

May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities

Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum

Aug 13, 2014: Cardium Announces Review in Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted'

May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy

Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To
Cardiovascular Gene Therapy For Treatment Of Heart Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Angina (Angina Pectoris), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Angina (Angina Pectoris) - Pipeline by Angionetics Inc, H1 2020
Angina (Angina Pectoris) - Pipeline by Ark Therapeutics Ltd, H1 2020
Angina (Angina Pectoris) - Pipeline by Caladrius Biosciences Inc, H1 2020
Angina (Angina Pectoris) - Pipeline by G. Pohl-Boskamp GmbH & Co KG, H1 2020
Angina (Angina Pectoris) - Pipeline by Hemostemix Inc, H1 2020
Angina (Angina Pectoris) - Pipeline by Imbria Pharmaceuticals Inc, H1 2020
Angina (Angina Pectoris) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
Angina (Angina Pectoris) - Pipeline by Kuhnle Pharmaceutical Co Ltd, H1 2020
Angina (Angina Pectoris) - Pipeline by Milestone Pharmaceuticals Inc, H1 2020
Angina (Angina Pectoris) - Pipeline by Signal Pharma Ltd, H1 2020
Angina (Angina Pectoris) - Pipeline by TSH Biopharm Corporation Ltd, H1 2020
Angina (Angina Pectoris) - Pipeline by VasThera Research Institute, H1 2020
Angina (Angina Pectoris) - Pipeline by XyloCor Therapeutics Inc, H1 2020
Angina (Angina Pectoris) - Dormant Projects, H1 2020
Angina (Angina Pectoris) - Dormant Projects, H1 2020 (Contd..1), H1 2020
Angina (Angina Pectoris) - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Angina (Angina Pectoris), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Targets, H1 2020

Number of Products by Stage and Targets, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Angionetics Inc

Ark Therapeutics Ltd

Caladrius Biosciences Inc

G. Pohl-Boskamp GmbH & Co KG

Hemostemix Inc

Imbria Pharmaceuticals Inc

Jiangsu Hengrui Medicine Co Ltd

Kuhnle Pharmaceutical Co Ltd

Milestone Pharmaceuticals Inc

Signal Pharma Ltd

TSH Biopharm Corporation Ltd

VasThera Research Institute

XyloCor Therapeutics Inc

I would like to order

Product name: Angina (Angina Pectoris) - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/A2182360FBBEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A2182360FBBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970